Review of the family Bochicidae : with new species and records (Arachnida: Pseudoscorpionida)

A history of the family is presented. All of the genera and species previously assigned to the family are reviewed, and 4 new species are described: Leucohya par va from Venezuela and Guyana, Mexobisium venii from Belize and Guatemala, M. dominicanum from the Dominican Republic, and Paravachonium sprousei from Mexico. Two subfamilies are established: Bochicinae (including the genera Antillobisium, Bochica, Troglobochica, Troglohya, and Vachonium) and Leucohyinae (including Apohya, Leucohya, Mexobisium, and Paravachonium)

A new cavernicolous pseudoscorpion belonging to genus Microcreagris

This remarkable new form was found among collections in the Peabody Museum lent by Dr. C. L. Remington…

New Terrestrial Isopods of the Genus Miktoniscus from Eastern United States (Crustacea: Isopoda: Oniscoidea)

Author Institution: Department of Biology, University of Rochester, Rochester, New Yor

The genus Tyrannochthonius in the eastern United States (Pseudoscorpionida: Chthoniidae). Part I. The historical taxa

All available material pertaining to Tyrannochthonius Chamberlin from the United States east of the Mississippi River has been examined. The range of the single species already described from this area, T. floridensis Malcolm and Muchmore, is extended. Ten new species are described here; all are troglobites from caves in Alabama

The genus Tyrannochthonius in the eastern United States (Pseudoscorpionida: Chthoniidae). Part II. More recently discovered species

Twenty-five new species of Tyrannochthonius, mostly cavernicolous, are described from Alabama, Florida, Kentucky, and Tennessee. Their relations are discussed, and a key is given for all species of the genus known from the United States east of the Mississippi River

Detection of Water Vapor in the Photosphere of Arcturus

We report detections of pure rotation lines of OH and H2O in the K1.5 III red-giant star Arcturus (alpha Bootis) using high-resolution, infrared spectra covering the regions 806-822 cm-1 (12.2-12.4 um) and 884-923 cm-1 (10.8-11.3 um). Arcturus is the hottest star yet to show water-vapor features in its disk-averaged spectrum. We argue that the water vapor lines originate from the photosphere, albeit in the outer layers. We are able to predict the observed strengths of OH and H2O lines satisfactorily after lowering the temperature structure of the very outer parts of the photosphere (log tau_500=-3.8 and beyond) compared to a flux-constant, hydrostatic, standard MARCS model photosphere. Our new model is consistently calculated including chemical equilibrium and radiative transfer from the given temperature structure. Possible reasons for a temperature decrease in the outer-most parts of the photosphere and the assumed break-down of the assumptions made in classical model-atmosphere codes are discussed.Comment: To appear in ApJ. See also http://www.astro.uu.se/~ryde/ART

Inhaled insulin for controlling blood glucose in patients with diabetes

Diabetes mellitus is a significant worldwide health problem, with the incidence of type 2 diabetes increasing at alarming rates. Insulin resistance and dysregulated blood glucose control are established risk factors for microvascular complications and cardiovascular disease. Despite the recognition of diabetes as a major health issue and the availability of a growing number of medications designed to counteract its detrimental effects, real and perceived barriers remain that prevent patients from achieving optimal blood glucose control. The development and utilization of inhaled insulin as a novel insulin delivery system may positively influence patient treatment adherence and optimal glycemic control, potentially leading to a reduction in cardiovascular complications in patients with diabetes

In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee

A 35-year-old female hepatitis B virus carrier chimpanzee was infused with one dose of a mixture of human monoclonal antibodies 9H9 and 4-7B (antibodies against hepatitis B virus surface antigen; HBsAg). Blood samples were taken before and up to 3 weeks after infusion. HBsAg and antibodies against HBsAg (anti-HBs) were quantified by radioimmunoassay and enzyme immunoassay. Free anti-HBs was never detected. Thirty min after the start of the infusion the HBsAg level was minimal with maximum loading of the chimpanzee HBsAg with human immunoglobulin. HBsAg complexes could be dissociated by acid treatment. The HBsAg level was completely restored on day 7. Similar results were obtained for the preS1-containing particles that may represent the infectious viral particles in the chimpanzee serum. A mouse monoclonal anti-HBs (HBs.OT40) was found to compete with 9H9 in artificial immune complexes with the pre-treatment HBsAg from the chimpanzee. Used as a conjugate, HBs.OT40 yielded a maximum decrease in the signal in the 30 min sample compared to non-competing anti-HBs conjugates. This indicates binding of HBsAg with 9H9 in the circulation of the chimpanzee. Immune-complexed 4-7B could not be detected by its corresponding 4-7B peptide conjugate, probably due to its low concentration in the complexes. It is concluded that human monoclonal anti-HBs can effectively reduce the level of HBsAg in serum from this chronic carrier. Monoclonals 9H9 and 4-7B may complement each other due to their different mechanisms of inactivation, probably with higher efficiency than that monitored by our HBsAg screening assays

Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear

Insulin exposure varies over 3 days of insulin infusion set (IIS) wear making day-to-day insulin dosing challenging for people with diabetes (PWD). Here we report insulin pharmacodynamic (PD) and pharmacokinetic (PK) data extending these observations to 7 days of IIS wear. PWD (A1C ≤8.5%, C-peptide tmax (P \u3c 0.001), Cmax (P \u3c 0.05), and mean residence time (P \u3c 0.0001). Area under the insulin concentration curve (AUC0–300) declined by ∼24% from days 0 to 7 (P \u3c 0.05). These results confirm/extend previous observations showing progressive acceleration of insulin exposure over IIS wear time. This may have implications for PWD and designers of closed-loop algorithms, although larger studies are necessary to confirm this. The study was registered in clinicaltrials.gov (NCT04398030)